10-QPeriod: Q1 FY2026

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2026

Filed April 29, 2026For Securities:ABT

Summary

Abbott Laboratories reported its first-quarter 2026 results, marked by significant strategic growth through the acquisition of Exact Sciences Corporation for approximately $20.6 billion. This transaction, largely funded by new debt, is expected to bolster Abbott's position in the cancer diagnostics market. Despite a challenging sales environment for Nutritional Products, overall net sales increased by 7.8% to $11.164 billion, driven by strong performance in Medical Devices and Established Pharmaceuticals, with a notable contribution from the new Cancer Diagnostics business. Financially, the company experienced a decrease in net earnings to $1.077 billion from $1.325 billion in the prior year, resulting in diluted EPS of $0.61, down from $0.76. This decline in profitability is largely attributable to increased operating costs, including those related to the Exact Sciences integration, and higher interest expenses associated with the acquisition financing. However, the company maintained a positive operating cash flow of $1.315 billion. Investors should note the significant increase in goodwill and intangible assets on the balance sheet due to the acquisition, alongside a substantial rise in long-term debt.

Financial Highlights

51 data points
Beta

Revenue

$11.16B

56.2% Gross Margin

Net Income

$1.08B

9.6% Net Margin

EPS (Diluted)

$0.61

Total Assets

$110.43B

Cash & Equivalents

$6.80B

Free Cash Flow

$916.00M

Financial Statements
Beta
Revenue$11.16B
Cost of Revenue$4.89B
Gross Profit$6.27B
R&D Expenses$767.00M
SG&A Expenses$3.74B
Operating Expenses$9.82B
Operating Income$1.34B
Net Income$1.08B
EPS (Basic)$0.62
EPS (Diluted)$0.61
Shares Outstanding (Basic)1.74B
Shares Outstanding (Diluted)1.75B

Key Highlights

  • 1Acquisition of Exact Sciences Corporation for approximately $20.6 billion completed on March 23, 2026, significantly expanding the Diagnostic Products segment, particularly in cancer diagnostics.
  • 2Total net sales grew 7.8% year-over-year to $11.164 billion, driven by Medical Devices (+13.2%) and Established Pharmaceuticals (+13.2%), while Nutritional Products saw a decline (-6.0%).
  • 3Net earnings decreased to $1.077 billion ($0.61 diluted EPS) from $1.325 billion ($0.76 diluted EPS) in the prior year, impacted by higher operating costs and interest expenses related to the Exact Sciences acquisition.
  • 4Operating cash flow remained robust at $1.315 billion, although slightly down from $1.417 billion in the prior year.
  • 5Long-term debt significantly increased by $19.742 billion to $29.638 billion, primarily to finance the Exact Sciences acquisition.
  • 6Goodwill and Intangible Assets saw substantial increases on the balance sheet, reflecting the Exact Sciences acquisition ($11.4 billion in goodwill and $12.8 billion in acquired intangible assets).
  • 7The company declared a quarterly dividend of $0.63 per share, an increase of 6.8% from the prior year's dividend.

Frequently Asked Questions

The acquisition of Exact Sciences for approximately $20.6 billion, completed on March 23, 2026, significantly impacted the balance sheet with an increase in goodwill by $11.4 billion and acquired intangible assets by $12.8 billion. This was financed primarily through $20 billion in long-term debt, leading to a substantial increase in interest expense. While the acquisition contributes to the Diagnostic Products segment, it also increased operating costs and contributed to a decrease in net earnings for the quarter.

The Medical Devices segment showed strong growth, increasing 13.2% excluding foreign exchange, led by Rhythm Management, Electrophysiology, and Heart Failure. The Established Pharmaceutical Products segment also grew by 13.2% excluding foreign exchange, driven by emerging markets. The Diagnostic Products segment grew 6.1% excluding foreign exchange, with the new Cancer Diagnostics business (from Exact Sciences) contributing $96 million in sales. However, the Nutritional Products segment experienced a decline of 6.0% excluding foreign exchange, attributed to lower sales volumes.

Abbott significantly increased its long-term debt by $19.742 billion in the quarter to finance the Exact Sciences acquisition, bringing the total to $29.638 billion. The company expects to repay $1.4 billion of the assumed Exact Sciences debt in 2026. Abbott maintains an investment-grade rating (A+ by S&P, Aa3 by Moody's) and expects to maintain this rating, indicating confidence in its ability to manage its increased leverage.

Abbott is involved in several significant legal proceedings, including ongoing lawsuits related to infant formula and investigations by the IRS for tax years 2017-2020, with substantial tax assessments proposed. The company is actively contesting these assessments and is in discussions with the IRS. Additionally, there is a tax assessment from Malaysian tax authorities. While Abbott believes its reserves for uncertain tax positions are appropriate and intends to defend its positions, the resolution of these matters, particularly the infant formula lawsuits, could be material to the company's financial position.